LEANDRO RESENDE | Oncology and precision medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

LEANDRO RESENDE
Rede Dor

LEANDRO RESENDE
Affiliation Rede Dor
Country Brazil
Scopus ID 57188977624
Documents 5
Citations 35
h-index 3
Subject Area Oncology and precision medicine
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

LEANDRO RESENDE is a researcher affiliated with Rede Dor in Brazil whose documented scholarly profile is associated with oncology and precision medicine.The Innovative Research Award profile presents this research activity within the broader context of contemporary cancer science, where molecular characterization, individualized treatment strategies, biomarkers, and evidence-based clinical decision-making increasingly intersect. Precision oncology seeks to connect biological information with clinically meaningful therapeutic choices. [1]

Abstract

The Innovative Research Award profile recognizes the research record of LEANDRO RESENDE, affiliated with Rede Dor, Brazil, in the field of oncology and precision medicine. The documented Scopus profile reports five scholarly documents, 35 citations, and an h-index of 3. [1] These indicators provide a bibliometric snapshot of published research and citation activity.Within modern oncology, precision medicine emphasizes the integration of molecular, clinical, and pathological information to support more individualized approaches to cancer investigation and treatment.

Keywords

  • Innovative Research Award
  • Oncology
  • Precision Medicine
  • Cancer Research
  • Biomedical Research
  • Research Impact

Introduction

Cancer research increasingly depends on interdisciplinary approaches that connect molecular biology, clinical medicine, pathology, genomics, and computational analysis. Precision medicine has developed as an important framework for identifying biological differences between tumors and using those differences to inform research and therapeutic strategies. [3]Against this background, researchers working across oncology contribute to a continually expanding evidence base.

Research Profile

LEANDRO RESENDE is affiliated with Rede Dor in Brazil and is represented in Scopus under Author ID 57188977624. The supplied profile records five documents, 35 citations, and an h-index of 3. [1] The stated subject area is oncology and precision medicine, placing the research profile within a clinically and scientifically significant field.

Research Contributions

Contemporary cancer frameworks emphasize multiple interacting characteristics of malignant disease, including genomic instability, cellular signaling, immune interactions, and the tumor microenvironment. [3]The documented bibliometric record offers measurable evidence of scholarly dissemination, while the specific scientific significance of individual publications should be evaluated through their methods, findings, citations, and subsequent use by other researchers.

Publications

The supplied Scopus record identifies five documents associated with the researcher. [1] Because complete publication titles, journal information, publication years, and DOI identifiers were not supplied with the profile data, this article does not assign specific publication details that cannot be independently established from the provided record.

Research Impact

The reported total of 35 citations indicates that the indexed documents have been cited within the scholarly literature. The h-index of 3 further describes a citation distribution in which at least three documents have each received at least three citations, subject to the indexing and counting methodology used by the database. [1]Citation metrics are useful descriptive measures but do not independently determine scientific quality or societal impact.

Award Suitability

The supplied research profile is aligned thematically with an award focused on oncology and cancer research because the stated subject area is oncology and precision medicine. The documented publication and citation record provides an objective basis for describing established scholarly activity. [1]Final award assessment should be based on the organizer’s published eligibility criteria, submitted evidence, peer or committee evaluation, and the originality and significance of the candidate’s research.

Conclusion

LEANDRO RESENDE’s supplied academic profile documents research activity associated with Rede Dor, Brazil, and the fields of oncology and precision medicine. The Scopus record reports five documents, 35 citations, and an h-index of 3, providing a concise bibliometric description of the researcher’s indexed scholarly output. [1]The Innovative Research Award profile places these activities within the wider development of precision oncology and evidence-based cancer research.

References

  1. Elsevier. (n.d.). Scopus author details: LEANDRO RESENDE, Author ID 57188977624. Scopus.
    https://www.scopus.com/pages/authors/57188977624
  2. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment. National Cancer Institute.
    https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
  3. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cell, 185(1), 31–41. DOI: 10.1016/j.cell.2021.12.029.
    https://doi.org/10.1016/j.cell.2021.12.029
  4. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17, 507–522. DOI: 10.1038/nrg.2016.86.
    https://doi.org/10.1038/nrg.2016.86
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Website.
    https://oncology.pencis.com/

Carlo Croce | Cancer Science | Innovative Research Award

Published on by Oncology

Innovative Research Award

Carlo Croce
Ohio State University, United States

                  Carlo Croce
Affiliation Ohio State University
Country United States
Scopus ID 7202975031
Documents 1,366
Citations 209,103
h-index 213
Subject Area Cancer Science
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-3788-1457

Carlo Croce is a cancer researcher affiliated with The Ohio State University whose research profile is centered on cancer biology, human cancer genetics and molecular mechanisms associated with malignancy. His institutional profile identifies cancer biology as an area of expertise and highlights human cancer genetics and microRNA research as major interests. [1] Bibliographic databases likewise identify his Ohio State affiliation and extensive publication record. [2]

Abstract

The Innovative Research Award recognition profile examines Carlo Croce in relation to contemporary cancer science and molecular oncology. Available institutional and bibliographic records associate his work with cancer biology, human cancer genetics and microRNA-related mechanisms. [1] His documented research activity includes a substantial body of peer-reviewed scientific literature addressing oncogenes, non-coding RNAs and cancer development. [3]

Keywords

Carlo Croce, Innovative Research Award, cancer science, cancer biology, oncology, human cancer genetics, microRNA, oncogenes, molecular oncology, Ohio State University.

Introduction

Cancer research increasingly integrates molecular genetics, cellular biology and translational science to understand how malignant transformation begins and progresses. Croce’s research has addressed molecular alterations associated with cancer, including oncogenes and regulatory mechanisms involving microRNAs. His published review on oncogenes discussed how molecular targets can contribute to the development of targeted anticancer strategies. [3]

Research Profile

The research profile is primarily situated within cancer biology and genetics. The Ohio State University profile identifies Cancer Biology & Genetics as an academic area and specifically lists human cancer genetics and the role of microRNAs in cancer among areas of expertise. [1] Bibliographic records further associate the researcher with a broad body of cancer-related publications and collaborations. [2]

Research Contributions

A significant theme of Croce’s research concerns the relationship between genetic alterations and malignant disease. His work on oncogenes has considered how genes involved in tumor initiation and progression can become relevant therapeutic targets. [3] His research has also examined microRNAs and their regulatory functions, contributing to broader investigation of non-coding RNA biology in cancer. [4]Research involving small non-coding RNAs has extended this molecular perspective into leukemia and related malignancies. A co-authored review published in Cancers examined small non-coding RNAs in leukemia and identified their relevance to cancer biology and potential therapeutic research. [5] These themes demonstrate the integration of molecular genetics with disease-focused oncology research.

Publications

Available scholarly records show an extensive publication history spanning cancer genetics, oncogenes, microRNAs and related molecular oncology topics. The Ohio State research portal lists more than one thousand research outputs associated with the researcher, while the current bibliographic author record identifies a similarly extensive body of indexed work. [2]

  • Oncogenes and cancer, New England Journal of Medicine, 2008.
  • Causes and consequences of microRNA dysregulation in cancer, Nature Reviews Genetics, 2009.
  • Small Non-Coding RNAs in Leukemia, Cancers, 2022. [5]

Research Impact

The supplied research metrics indicate a substantial bibliometric footprint, including 1,366 documents, 209,103 citations and an h-index of 213. Bibliographic information available through the author’s indexed profile confirms a very high level of publication and citation activity, although such metrics can change as databases are updated.Beyond quantitative indicators, the research record reflects sustained engagement with fundamental questions in cancer biology. Publications addressing oncogenes and microRNA regulation have helped frame molecular mechanisms as important components of modern cancer research and therapeutic investigation.

Award Suitability

Based on the supplied profile information, Carlo Croce demonstrates characteristics relevant to an Innovative Research Award in oncology and cancer research. The combination of a long-standing cancer research program, extensive scholarly output, substantial citation activity and research focused on molecular mechanisms provides a strong evidence base for consideration. [1] Final award decisions should remain subject to the event’s formal eligibility criteria and independent review.

Conclusion

Carlo Croce’s academic profile is closely associated with cancer biology, molecular genetics and oncology research. Institutional and bibliographic sources document extensive research activity and a substantial scholarly impact, while representative publications demonstrate sustained work on oncogenes, microRNAs and cancer-related molecular mechanisms. [2] On the basis of the supplied metrics and documented research themes, the profile is relevant to recognition under an innovative cancer research award.

References

  1. The Ohio State University. (n.d.). Carlo Croce — Molecular, Cellular and Developmental Biology Program. Ohio State University.
    https://mcdb.osu.edu/people/croce.5
  2. Elsevier. (n.d.). Carlo Maria Croce — Scopus author details, Author ID 7202975031. ScienceDirect.
    https://www.sciencedirect.com/author/7202975031/carlo-maria-croce
  3. Croce, C. M. (2008). Oncogenes and cancer. New England Journal of Medicine, 358(5), 502–511.
    https://doi.org/10.1056/NEJMra072367
  4. Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics, 10, 704–714.  https://doi.org/10.1038/nrg2634
  5. Balatti, V., & Croce, C. M. (2022). Small Non-Coding RNAs in Leukemia. Cancers, 14(3), 509.
    https://doi.org/10.3390/cancers14030509

Nour Abu Jayab | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Nour Abu Jayab
University of Sharjah

                 Nour Abu Jayab
Affiliation University of Sharjah
Country United Arab Emirates
Scopus ID 58147288600
Documents 5
Citations 110
h-index 4
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research

Nour Abu Jayab is a researcher affiliated with the University of Sharjah whose scholarly activities contribute to the advancement of cancer cell biology and related biomedical investigations. Her publication record, citation performance, and research visibility demonstrate active engagement in contemporary oncology research. The Innovative Research Award recognizes scientific contributions that support the understanding of cancer mechanisms, translational biology, and evidence-based innovation within oncology and cancer research disciplines.[1][2]

Abstract

Nour Abu Jayab has established a developing research profile within cancer cell biology through contributions focused on understanding cellular mechanisms associated with cancer progression and therapeutic response. Her scholarly output demonstrates engagement with contemporary oncology challenges, including translational research and biomedical innovation. With a documented publication record and measurable citation impact, her work has contributed to scientific discussions within oncology-related disciplines. The combination of research productivity, interdisciplinary collaboration, and influence reflected through citation metrics supports recognition for innovative scientific achievement within the framework of the International Research Awards on Oncology and Cancer Research.[1][2]

Keywords

Cancer Cell Biology, Oncology Research, Translational Medicine, Cancer Mechanisms, Biomedical Research, Cellular Signaling, Tumor Biology, Scientific Innovation, Cancer Therapeutics, Research Impact

Introduction

Cancer research continues to rely on innovative investigations that improve understanding of cellular behavior, disease progression, and treatment response. Nour Abu Jayab contributes to this field through scholarly activities focused on cancer cell biology, supporting scientific knowledge relevant to modern oncology and translational biomedical research.[1]

Research Profile

Affiliated with the University of Sharjah, Nour Abu Jayab has developed a research portfolio within oncology-related disciplines. Her Scopus-indexed publications, citation performance, and measurable h-index indicate growing academic visibility and engagement with topics connected to cancer biology and biomedical sciences.[1][2]

Research Contributions

Her research contributions support understanding of biological processes relevant to cancer development and treatment. Through peer-reviewed publications, she has participated in advancing scientific evidence, encouraging interdisciplinary collaboration, and contributing to the broader knowledge base that informs future oncology investigations.[1][3]

Publications

The researcher maintains a Scopus-indexed publication record consisting of five documented scholarly works. These publications collectively address themes associated with cancer biology and biomedical research, contributing to scientific communication and supporting evidence-based advancement within oncology-related fields.[1]

Research Impact

With more than one hundred citations and an established h-index, Nour Abu Jayab’s research demonstrates measurable scholarly influence. Citation activity indicates that her publications have been referenced by other researchers, reflecting relevance and contribution to ongoing discussions within cancer and biomedical sciences.[1][2]

Award Suitability

The Innovative Research Award recognizes originality, scientific contribution, and research influence. Based on documented publication metrics, citation performance, and engagement in cancer cell biology, Nour Abu Jayab demonstrates characteristics aligned with award criteria emphasizing innovation, academic excellence, and contributions to oncology research.[1]

Conclusion

Nour Abu Jayab’s scholarly profile reflects active participation in cancer cell biology research. Her publication record, citation impact, and contribution to oncology-related knowledge support recognition within international research award programs that value innovation, scientific rigor, and meaningful advancement of biomedical science.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Nour Abu Jayab, Author ID 58147288600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58147288600
  2. Abu Jayab, N., Abed, A., Talaat, I. M., & Hamoudi, R. (Year). The molecular mechanism of NF-κB dysregulation across different subtypes of renal cell carcinoma.https://pmc.ncbi.nlm.nih.gov/articles/PMC12147641/
  3. ResearchGate. (n.d.). Nour Abu Jayab Research Profile and Publications.https://www.researchgate.net/profile/Nour-Abu-Jayab

Asokan R | Tumor | Research Excellence Award

Published on by Oncology

Dr. Asokan R | Tumor | Research Excellence Award

Professor | Kongunadu College of Engineering and Technology | India 

Dr. Asokan R is a senior academic leader and researcher, currently serving as the Principal of Kongunadu College of Engineering and Technology, with more than three decades of experience in engineering education and administration. He holds a PhD from Anna University and has strong academic credentials from BITS Pilani, Pondicherry Engineering College, and Kongu Engineering College. His expertise includes telecommunications, image processing, wireless networks, network security, optimization techniques, and the Internet of Things. He has led and coordinated several funded research projects, faculty development programs, and international conferences. Dr. Asokan has an extensive publication record in areas such as deep learning, medical imaging, and network optimization. His contributions have been recognized with prestigious honors including the AICTE Lilavati Award, Best Principal Award, and multiple excellence awards. He is an active member of professional bodies like IEEE, CSI, IETE, and ISTE, contributing widely to academic councils and technical committees.

Citation Metrics (Scopus)

1231
900
600
300
0

Citations

1231

h-index

18

i10-index

30

Citations

h-index

i10-index

View ResearchGate Profile View Google Scholar Profile
 View Linkedin Profile

Featured Publications


A review of Quality of Service (QoS) routing protocols for mobile Ad hoc networks

– Proc. IEEE International Conference on Wireless Communication and Sensor Computing, 2010

Manuel Fernandez-Escabias | Cancer Science | Research Excellence Award

Published on by Oncology

Mr. Manuel Fernandez-Escabias | Cancer Science | Research Excellence Award

Predoctoral Researcher | University of Granada | Spain 

Mr. Manuel Fernández Escabias is a predoctoral researcher at the University of Granada with an outstanding academic record in Sport Sciences and a strong focus on exercise, physiology, and oncology. He is currently pursuing a PhD in biomedicine on multidisciplinary prehabilitation and rehabilitation to reduce postoperative complications in colon cancer surgery. Since joining the PROFITH research group in 2021, he has actively contributed to major national projects such as ONCOFIT and RESET, often serving as Project Manager. His work spans exercise oncology, virtual reality in rehabilitation, and lifestyle-based interventions for improving surgical outcomes. Despite his young age, he has authored multiple Q1 and D1 journal articles and has participated in over 30 national and international conferences. He has received several prestigious awards, including the Blas Cabrera Scholarship, Best Master’s Thesis Award, and University of Granada Talent Award. Alongside his research, he is also building a strong teaching profile in physiology and exercise science while mentoring undergraduate and postgraduate students.

 

Citation Metrics (Google Scholar)

49
40
30
20
10
0

Citations

49

h-index

3

i10-index

2

Citations

h-index

i10-index

View ResearchGate Profile View Google Scholar Profile

Featured Publications


Modulation of fatty acid metabolism via lactate-HCA1 signaling: potential therapeutic implications

– American Journal of Physiology: Cell Physiology, 2025 (1 citation)

Raheleh Farahzadi | Stem Cell Therapy | Women Researcher Award

Published on by Oncology

Assoc. Prof. Dr. Raheleh Farahzadi | Stem Cell Therapy | Women Researcher Award 

Tabriz University of Medical Sciences | Iran

 

Assoc. Prof. Dr. Raheleh Farahzadi is an accomplished biochemist with a PhD and over nine years of experience in higher education, research, and academic leadership in biochemistry, cell, and molecular biology. She is internationally recognized as a top 2% most influential scientist worldwide (Stanford–Elsevier, 2024 and 2025) with a strong research focus on stem cells, cancer biology, and regenerative medicine. She has led 16 university, national, and international research projects and published 69 peer-reviewed articles with an H-index of 35 and over 3,300 citations. An experienced educator, she has delivered diverse biomedical courses and mentored numerous undergraduate, master’s, and PhD students to successful academic outcomes. Her expertise spans advanced cellular, molecular, and stem cell techniques, grant writing, and scientific publishing. She serves as an editor for leading journals and as a reviewer for over 400 manuscripts in high-impact journals. Currently based in Australia, she actively contributes to teaching, research, and collaborative biomedical innovation.

Citation Metrics (Google Scholar)

3374
2500
1500
500
0

Citations

3374

h-index

35

i10-index

58

Citations

h-index

i10-index

View ORCID Profile View Google Scholar Profile
 View ResearchGate Profile

Featured Publications

 

Ezzatollah Fathi | Cancer Stem Cell | Best Academic Researcher Award

Published on by Oncology

Prof. Ezzatollah Fathi | Cancer Stem Cell | Best Academic Researcher Award 

 University of Tabriz | Iran 

Prof. Ezzatollah Fathi is a senior academic and biomedical scientist serving as Professor at the University of Tabriz and Academic Sessional Lecturer at Victoria University, Australia, with extensive experience in teaching, research, and academic leadership. He holds a PhD in Clinical Pathology from the University of Tehran and a Doctorate in Veterinary Medicine from Ferdowsi University of Mashhad, both completed with high academic distinction. His teaching expertise covers biochemistry, hematology, clinical pathology, and clinical sciences across undergraduate, postgraduate, and doctoral programs. His research primarily focuses on stem cell biology, regenerative medicine, and cellular and molecular mechanisms of disease. Dr. Fathi has published more than 50 peer-reviewed articles and has served as principal investigator for several national and international research grants. He has supervised numerous undergraduate and postgraduate students, leading to successful theses, publications, and conference presentations. His scholarly impact has been internationally recognized through repeated inclusion in the Stanford–Elsevier list of the world’s top 2% most influential scientists.

Citation Metrics (Scopus)

2054
1500
1000
500
0

Citations

2,054

Documents

79

h-index

34

Citations

Documents

h-index

View Scopus Profile View Google Scholar Profile
 View ORCID Profile

Featured Publications

Ogadimma Arisukwu | cancer | Editorial Board Member

Published on by Oncology

Dr. Ogadimma Arisukwu | cancer | Editorial Board Member

Research Scholar | Landmark University | Nigeria

Dr. Ogadimma Arisukwu is an accomplished social scientist and lecturer at Landmark University, Omu-Aran, Nigeria, whose scholarship spans social policy, public health systems, community studies, and socio-cultural dynamics within African societies. His research examines the intersection of governance, health service delivery, livelihood realities, and culturally rooted behavioral responses, with a particular focus on how institutional structures shape societal well-being. Dr. Arisukwu’s work offers evidence-based insights into contemporary sociological challenges, including health insurance utilization, socio-cultural perceptions of reproductive technologies, and emerging threats such as employment scams that affect vulnerable populations. His publications demonstrate strong methodological rigor, integrating qualitative and quantitative approaches to understand lived experiences, inform policy reforms, and strengthen community resilience. As an active academic contributor, he has authored numerous peer-reviewed studies in reputable international journals, contributing to global debates on health equity, social justice, and cultural determinants of human behavior. Dr. Arisukwu engages in interdisciplinary collaborations with scholars across Nigeria and beyond, promoting research that bridges academic inquiry and practical societal needs. His work carries substantial societal relevance, supporting better-informed policymaking, advancing inclusive healthcare practices, and deepening understanding of cultural frameworks that shape public perception and behavior. Through sustained research productivity and community-centered academic engagement, he has established himself as a respected voice in sociology and social policy research. Dr. Arisukwu’s academic influence and research productivity are reflected in his metrics 212 citations, 31 documents, and an h-index of 9.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Job scams in Ibadan (2024) Arisukwu, O., et al. (2024). Job advertisements and lived experiences of victims of job scams in Ibadan, Nigeria. International Journal of Sociology and Social Policy.
(Citations: 2)

2. NHIS–HMO healthcare perception (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Healthcare service delivery perception among NHIS-HMO enrollees in Lagos hospitals. Humanities and Social Sciences Communications. (Citations: 2)

3. Religious & cultural interpretations of artificial insemination (2023) Authors include: Arisukwu, O., et al. (2023). Religious and cultural interpretations of artificial insemination in South-West Nigeria. AJOG Global Reports. (Citations: 4)

4. Attitudes of medical personnel in Lagos hospitals (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Perception among NHIS–HMO enrolees of the attitudes of medical personnel during outpatient care in Lagos hospitals. International Journal of Environmental Research and Public Health, 20(2). https://doi.org/10.3390/ijerph20021218

5. Youth gambling in Nigeria (2021)

Adebisi, T., Alabi, O., Arisukwu, O., & Asamu, F. (2021). Gambling in transition: Assessing youth narratives of gambling in Nigeria. Journal of Gambling Studies. https://doi.org/10.1007/s10899-020-09982-x

Hifzur R Siddique | Cancer Science | Editorial Board Member

Published on by Oncology

Assist. Prof. Dr. Hifzur R Siddique | Cancer Science | Editorial Board Member

Assistant Professor | Aligarh Muslim University | India

Dr. Hifzur R. Siddique is a distinguished researcher and academic at Aligarh Muslim University, India, specializing in cancer biology, nanomedicine, stem cell research, chemoresistance mechanisms, and translational therapeutics. His work spans the synthesis and characterization of metal oxide nanoparticles with anticancer potential, epigenetic regulation in cancer, and preclinical evaluation of natural compounds like lupeol for chemotherapeutic applications. Dr. Siddique has contributed significantly to methodological advancements, including the use of Drosophila melanogaster models for DNA damage studies and luciferase-based reporter assays for kinase activity assessment. With a robust portfolio of 103 publications in high-impact journals, book chapters, and systematic reviews, he collaborates extensively with over 340 co-authors worldwide, reflecting his leadership in multidisciplinary cancer research. His studies not only advance fundamental understanding of tumor biology but also address translational challenges, bridging laboratory findings to clinical and societal impact. Dr. Siddique’s research has influenced global guidelines on rare malignancies such as NUT carcinoma and contributed to the development of nanocomposite-based therapeutic strategies. His work embodies a commitment to improving cancer outcomes, fostering innovation, and mentoring the next generation of scientists in oncology and biomedical sciences. Dr. Siddique’s academic influence and research productivity are reflected in his metrics 3,083 citations, 103 documents, and an h-index of 30.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

Siddique, H. R., & Saleem, M. (2011). Beneficial health effects of lupeol triterpene: A review of preclinical studies. Life Sciences, 88(7-8), 285–293. [Cited by 477]

Siddique, H. R., & Saleem, M. (2012). Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences. Stem Cells, 30(3), 372–378. [Cited by 419]

Mishra, S. K., Siddique, H. R., & Saleem, M. (2012). S100A4 calcium-binding protein is key player in tumor progression and metastasis: Preclinical and clinical evidence. Cancer and Metastasis Reviews, 31(1), 163–172. [Cited by 212]

Siddique, H. R., Chowdhuri, D. K., Saxena, D. K., & Dhawan, A. (2005). Validation of Drosophila melanogaster as an in vivo model for genotoxicity assessment using modified alkaline Comet assay. Mutagenesis, 20(4), 285–290. [Cited by 146]

Fatma, H., Maurya, S. K., & Siddique, H. R. (2022). Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance. Seminars in Cancer Biology, 83, 166–176. [Cited by 136]

Jun Lu | Cancer | Editorial Board Member

Published on by Oncology

Prof. Jun Lu | Cancer | Editorial Board Member

Professor | Chengdu University of Traditional Chinese Medicine | China

Dr. Jun Lu is a distinguished researcher at Chengdu University of Traditional Chinese Medicine, China, specializing in cancer nanomedicine, biomaterials, and translational therapeutics. His work focuses on the design and development of multifunctional nanoplatforms, including engineered chitosan nanoparticles, aptamer-conjugated chemotherapeutics, and self-gelling biomaterials for applications in tumor therapy, wound healing, and infectious disease management. Dr. Lu integrates molecular biology, materials science, and bioengineering to advance innovative therapeutic strategies, such as modulating tumor microenvironments, orchestrating DNA damage pathways in colorectal carcinoma, and promoting MRSA-infected wound healing. He has authored 78 publications in high-impact journals including Journal of Translational Medicine, Chemical Engineering Journal, Carbohydrate Polymers, and Nano Research, reflecting strong expertise in nanobiotechnology and translational oncology. His extensive collaborations with over 380 co-authors worldwide demonstrate his leadership in multidisciplinary research networks, bridging fundamental science with clinical applications. Beyond academic contributions, Dr. Lu’s work has significant societal impact by enabling advanced therapies for cancer, infectious diseases, and tissue repair, providing novel solutions to global health challenges. His research emphasizes translational relevance and real-world applicability, contributing to safer, more effective, and innovative therapeutic modalities. Dr. Lu’s academic influence and research productivity are reflected in his metrics 2,421 citations, 78 documents, and an h-index of 24.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

Lu, J., Zhang, H., Hou, J., Li, X., Hu, X., Hu, Y., Easton, C. D., Li, Q., Sun, C., … (2020). Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks. Nature Materials, 19(7), 767–774. Cited by: 495

Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. International Journal of Molecular Sciences, 18(8), 1683. Cited by: 384

Lu, J., Jiang, F., Lu, A., Zhang, G. (2016). Linkers having a crucial role in antibody–drug conjugates. International Journal of Molecular Sciences, 17(4), 561. Cited by: 352

Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., … (2012). Restoring Methicillin-Resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Science Translational Medicine, 4(126), 126ra35.
Cited by: 328

Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., … (2017). A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 8(1), 1390.
Cited by: 275